Poland· PL-100358856
Obizur
A susoctocog alfa product containing susoctocog alfa. pozbawiony domeny b antyhemolityczny czynnik viii (rekombinowany), sekwencja świni., registered in Poland by Baxalta Innovations GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Susoctocog alfa is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD14 (susoctocog alfa), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Susoctocog alfa · ATC B02BD14
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Susoctocog alfa. Pozbawiony domeny B antyhemolityczny czynnik VIII (rekombinowany), sekwencja świni.
- Manufacturer
- Baxalta Innovations GmbH
- Country
- Poland (PL)
- ATC code
- B02BD14
- ATC class
- Susoctocog alfa
- Defined daily dose
- 14 TSD, E
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991281113
- gtin05909991281120
- gtin05909991281137
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B02BD14
Susoctocog alfa, as other registers publish it.
- DenmarkObizurBaxalta Innovations GmbH
- FinlandObizurBaxalta Innovations GmbH
- NorwayObizurBaxalta Innovations GmbH
- IcelandObizurBaxalta Innovations GmbH
- CzechiaOBIZURBaxalta Innovations GmbH, Vídeň
- CzechiaOBIZURBaxalta Innovations GmbH, Vídeň
- CzechiaOBIZURBaxalta Innovations GmbH, Vídeň
- BelgiumObizur 500 UBaxalta Innovations
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2852d741-6b56-43dd-9e1f-cd1eaf769ebc GET /v1/drugs/2852d741-6b56-43dd-9e1f-cd1eaf769ebc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "500 j./ml",
"packaging": "05909991281113 ¦ Rpz ¦ EU/1/15/1035/001 ¦ 112553\n1 fiol. 500 j. /ml proszku ¦ 1 amp.-strzyk. rozpuszczalnik + przyrząd do przenoszenia roztworu\n05909991281120 ¦ Rpz ¦ EU/1/15/1035/002 ¦ 112555\n5 fiol. 500 j. /ml proszku ¦ 5 amp.-strzyk. rozpuszczalnik + przyrząd do przenoszenia roztworu\n05909991281137 ¦ Rpz ¦ EU/1/15/1035/003 ¦ 112556\n10 fiol. 500 j. /ml proszku ¦ 10 amp.-strzyk. rozpuszczalnik + przyrząd do przenoszenia roztworu",
"substance": "Antyhemolityczny czynnik VIII (rekombinowany), sekwencja świni 500 j./ml",
"common_name": "Susoctocog alfa. Pozbawiony domeny B antyhemolityczny czynnik VIII (rekombinowany), sekwencja świni.",
"pl_product_id": "100358856",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about susoctocog alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.